Our portfolio of companies

Eykona develops state-of-the-art imaging solutions to capture dermal characteristics and shape from the human body.

Oxtox develops medical devices for the detection of specific drugs in the human system.

Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Developing ultra thin coatings using breakthrough approaches to surface modification.

Aurox was established to research, develop, manufacture and commercially exploit products in the field of confocal microscopy and automated pathology slide scanners.

Big data and analysis company focused on enabling reproducibility in chemistry.

Particle Therapeutics is a drug delivery company developing innovative particle formulation and drug delivery technologies to improve the efficacy and administration of a range of pharmaceuticals.

Oxford Medistress is commercialising a novel in vitro blood test device which aims to provide the first objective, quantitative measurement of stress.

TdeltaS is committed to developing science-based proprietary products that sit at the interface of food and pharmaceuticals - nutraceuticals - and offer real improvement in human physical and mental performance.

Velocys, previously Oxford Catalysts, produces speciality catalysts for the generation of clean fuels, from both conventional fossil fuels and renewable sources such as biomass.

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

Oxbridge Pulsar Sources (OPS) is researching and developing novel radio transmitting antennas, based on new principles.